The FDA has accepted Gilead Sciences’ new drug application for a single-tablet, once-daily HIV treatment combination and ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ...

A new proposal could make it easier for patients to access breakthrough medical devices through Medicare insurance.

KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

SC allowed classification of Odomos under HSN 38089191 to stand, holding that market identity and consumer understanding ...

Shattuck Labs, Inc. (NASDAQ:STTK) is one of the best performing small cap stocks so far in 2026. Cantor Fitzgerald initiated ...

HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases ...

Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy followin ...

Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic ...

Endometriosis, a chronic inflammatory disease that affects approximately one in ten women of reproductive age—around 190 ...

An examination of litigation trends involving the Illinois Genetic Information Privacy Act (GIPA), which regulates the ...